Carastock.

Nov 27, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ... Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults ...Cara Therapeutics Inc (CARA) stock is higher by 5.42% while the S&P 500 is lower by -0.08% as of 1:37 PM on Thursday, Apr 7. CARA has risen $0.69 from the previous closing price of $12.73 on volume of 256,141 shares. Over the past year the S&P 500 is higher by 9.75% while CARA is lower by -49.42%.Aug 24, 2021 · CARA stock was up 2.8% as of Tuesday afternoon. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article. Feb 26, 2016 10:50 AM EST. NEW YORK ( TheStreet) -- Cara Therapeutics ( CARA) - stock is down by 36.02% to $4.42 on heavy trading volume on Friday, after the FDA placed a trial for the company's ...

According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of 1,327.36%. The lowest target is $1.00 and the highest is $28. On average, analysts rate CARA stock stock as a strong buy.

Download stock pictures of Cara on Depositphotos ✓ Photo stock for commercial use - millions of high-quality, royalty-free photos & images.

Discover historical prices for CARA stock on Yahoo Finance. View daily, …Cara Therapeutics stock news, updates & related news. Find out why Cara Therapeutics's (CARA) news sentiment is 13.38% more negative in relation to stocks ...Track Cara Therapeutics Inc (CARA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsCARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus.

Nov 29, 2023 · Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus.

May 25, 2023 at 3:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid, seeing as almost ...

What happened. Shares of Cara Therapeutics ( CARA -5.11%) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study ...Cara Therapeutics Stock (NASDAQ: CARA) stock price, news, charts, stock research, profile.Cara Therapeutics' current financial performance and market outlook do not paint an encouraging picture for investors. Find out why CARA stock is a Sell.Cara Therapeutics Inc’s ( CARA) price is currently down 34.15% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $6.58. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $7.40. Year to date, Cara Therapeutics Inc’s stock is ...Cara Therapeutics Stock Earnings. The value each CARA share was expected to gain vs. the value that each CARA share actually gained. Cara Therapeutics ( CARA) reported Q3 2023 earnings per share (EPS) of -$0.52, meeting estimates of -$0.52 by 0.60%. In the same quarter last year, Cara Therapeutics 's earnings per share (EPS) was -$0.43.

Cara Therapeutics (CARA) Company Description. Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic ...Over the last four quarters, the company has surpassed consensus EPS estimates two times. Cara, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.26 ...A high-level overview of Cara Therapeutics, Inc. (CARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The current price of CARA is $0.96. The 52 week high of CARA is $12.81 and 52 week low is $0.90. The next earnings date of Cara Therapeutics Inc (CARA) is 2024-03-06 Est.. Subject. Date.Top price targets Weekly price targets Monthly price targets Yearly price targets Intraday price targets . As on 19 Mon Sep 2022 Current price of Cara Therapeutics, Inc. CARA is 9.84 and trend of stock is towards upside and stock can be bought for price targets of 10.27, 10.41, 10.52, 10.6, 10.62, 11.68, 10.82Created with Highstock 2.1.8. Cara Therapeutics Inc. Annual stock financials by MarketWatch. View the latest CARA financial statements, income statements and financial ratios.

Earnings Date. Feb 13, 2024 - Feb 19, 2024. Forward Dividend & Yield. 1.84 (16.00%) Ex-Dividend Date. Nov 15, 2023. 1y Target Est. 26.50. Fair Value is the appropriate price for …Cara Therapeutics Inc’s ( CARA) price is currently down 34.15% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $6.58. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $7.40. Year to date, Cara Therapeutics Inc’s stock is ...

The latest analyst coverage could presage a bad day for Cara Therapeutics, Inc. (NASDAQ:CARA), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked.Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds …Cara Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CARA updated stock price target summary. The standard deviation of Shamrock Corp, stock is 16 percent. The standard deviation of Cara Co. stock is 12 percent, The covariance between these two stocks is 72. What is the correlation between Shamrock. and Cara stock? Round your answer to four decimal places.Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript November 13, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.5. Operator: Good afternoon. My name is Latif and I will be your conference facilitator. I would like to ...CARA stock was up 2.8% as of Tuesday afternoon. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article.Interactive Chart for Cara Therapeutics, Inc. (CARA), analyze all the data with a huge range of indicators.

CARA Stock Summary. The ratio of debt to operating expenses for CARA THERAPEUTICS INC is higher than it is for about merely 4.66% of US stocks. With a year-over-year growth in debt of -65.15%, CARA THERAPEUTICS INC's debt growth rate surpasses only 3.38% of about US stocks. In terms of volatility of its share price, CARA is more volatile than ...

CARA stock returns are also predicted based on historical data. According to our research, CARA stock is a bad long-term investment. CARA share price has been in a bear cycle for the past year. Cara Therapeutics, Inc. stock trend is negative. Cara Therapeutics company info. Industry:

Based on 2 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $4.00 with a high ...The drop in Cara Therapeutics stock was even more severe, plummeting 27% in after-hours trading. Investors had higher hopes for the biopharmaceutical company's rollout of injections of its Korsuva ...It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...As of March 10, 2023, 4:00 PM CST, Cara Therapeutics Inc’s stock price was $6.06. Cara Therapeutics Inc is down 5.16% from its previous closing price of $6.39. During the last market session, Cara Therapeutics Inc’s stock traded between $6.24 and $6.71. Currently, there are 53.76 million shares of Cara Therapeutics Inc stock available for ...Mar 7, 2023 · That is an increase of 297.20% in revenues from the year-ago report and is 79.93% lower than consensus estimates set at $16.3 million. The stock is down 29.89% to $7.03 after the report. The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease. Browse Getty Images' premium collection of high-quality, authentic Cara stock photos, royalty-free images, and pictures. Cara stock photos are available in ...Find the latest Cara Therapeutics, Inc. (CARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.

As of March 10, 2023, 4:00 PM CST, Cara Therapeutics Inc’s stock price was $6.06. Cara Therapeutics Inc is down 5.16% from its previous closing price of $6.39. During the last market session, Cara Therapeutics Inc’s stock traded between $6.24 and $6.71. Currently, there are 53.76 million shares of Cara Therapeutics Inc stock available for ...Compare with up to 5 Stocks. On Friday morning 12/01/2023 the Cara Therapeutics Inc share started trading at the price of $0.96. Compared to the closing price on Thursday 11/30/2023 on NAS of $0. ...Jun 27, 2023 · Cara Therapeutics Inc ( CARA) has risen Tuesday morning, with the stock increasing 5.25% in pre-market trading to 3.41. CARA's short-term technical score of 10 indicates that the stock has traded less bullishly over the last month than 90% of stocks on the market. In the Biotechnology industry, which ranks 110 out of 146 industries, the stock ... Instagram:https://instagram. td share pricenasdaq cdmois the stockmarket open todayfive dollar stocks Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis. sonos company stockmutf prgfx CARA Stock 12 Months Forecast. $14.10. (1230.19% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $14.10 with a high forecast of $25.00 and a low forecast of $3.50. The average price target represents a 1230.19% change from the last price of $1.06. The latest analyst coverage could presage a bad day for Cara Therapeutics, Inc. (NASDAQ:CARA), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked.Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds … o stock dividend history CARA U.S.: Nasdaq Cara Therapeutics Inc. Watch NEW Set a price target alert Premarket Last Updated: Nov 28, 2023 6:54 a.m. EST Delayed quote $ 1.0000 0.07 7.37% Before Hours Volume: 1 Advanced...Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Aug 11, 2021 · The PEG ratio is a company's P/E ratio divided by the annual earnings growth rate and is typically around 1 for a fairly valued company. Working backward from a PEG ratio of 1, I forecasted a $51 ...